effect of ivermevectin and brimonidine combination in rosacea

preparation and clinical evaluation of combination of ivermectin and brimonidine topical formulation for treatment of rosacea

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161207031288N7

Enrollment

Registered

2021-01-31

Start date

2020-11-21

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rosacea. rosacea

Interventions

Intervention group: Brimonidine/Ivermectin topical cream twice a day for 8 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Having rosacea disease treatment received in last three months men and women over 18 years

Exclusion criteria

Exclusion criteria: More than 5 inflammatory acne lesions Special forms of rosacea in addition to Dermatosis Seborrheic dermatits Acute lupus erythematosus demodicosis actinic telangiectasia Hypersensitivity to brimonidine/Ivermectin

Design outcomes

Primary

Measure	Time frame
Severity of lesions according to and Clinician Erythema Assessment (CEA). Timepoint: Before treatment and 4 and 8 weeks later. Method of measurement: physical exam.	—

Secondary

Measure	Time frame
Severity of lesions according to Patient Self-Assessment (PSA). Timepoint: Before treatment and 4 and 8 weeks later. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaman Ahmad Nasrollahi

Center For Research And Training In Skin Diseases And Leprosy

snasrollahi@tums.ac.ir+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026